For how we live.
10 articles published between November 20, 2025 and November 8, 2026.
A phase 2 trial gave ivonescimab, alone or with chemotherapy, to people with operable non-small-cell lung cancer. With chemotherapy, 70% had a major pathological response — but there was no control arm.
In PANKU-Lung01, 432 people with EGFR-mutated NSCLC that progressed on a third-generation EGFR tablet got izalontamab brengitecan or chemotherapy. Median progression-free survival was 11.1 versus 5.7 months.
In HERON-Lung01, 498 people in China with EGFR-mutated NSCLC that had progressed after a targeted drug were randomised to ruzaltatug rezetecan or chemotherapy. Median progression-free survival was 8.3 versus 5.4 months.
In a phase 3 trial, 314 people with EGFR-mutated, MET-amplified NSCLC progressing after a targeted drug were randomised to dalmelitinib plus aumolertinib or chemotherapy. Median PFS was 6.2 versus 4.4 months.
In Krascendo 1, 338 patients with previously treated KRAS G12C NSCLC were randomised to divarasib or to sotorasib or adagrasib. Median progression-free survival was 9.8 versus 5.7 months, and survival 17.7 versus 12.0.
The publicly funded E4512 trial found two years of crizotinib after surgery did not prolong disease-free survival against observation, with a hazard ratio of 1.08 and no safety upside.
The final analysis of Roche's phase 3 trial found the anti-TIGIT antibody did not significantly extend progression-free or overall survival when added to atezolizumab in 521 patients.
In the phase 3 SWOG/NRG S1914 trial, adding atezolizumab to stereotactic radiotherapy for high-risk, inoperable early lung cancer left 2-year survival at 82% in both groups and caused more serious side effects.
In the phase 3 LIBRETTO-432 trial, adjuvant selpercatinib raised two-year event-free survival to 92% from 61% in resected stage II-IIIA RET fusion-positive lung cancer. The trial was small and survival is unproven.
Hyrnuo (sevabertinib) is cleared for previously treated HER2-mutant NSCLC on response rate alone. The confirmatory trial that must justify it does not report until 2029.